Chong Insun, Wang Kevin Yuqi, Lincoln Christie M
Department of Radiology, Baylor College of Medicine, One Baylor Plaza, BCM 360, Houston, TX 77030, United States.
Department of Radiology, Baylor College of Medicine, One Baylor Plaza, BCM 360, Houston, TX 77030, United States.
Clin Imaging. 2019 Mar-Apr;54:53-56. doi: 10.1016/j.clinimag.2018.11.005. Epub 2018 Nov 14.
Fingolimod is an oral medication approved by the Food and Drug Administration in 2009 for the treatment of relapsing remitting multiple sclerosis (RRMS). Initial clinical trials did not show a significantly increased rate of serious infections with fingolimod therapy. However, a mildly increased risk of less serious infections, such as varicella zoster virus and herpes simplex virus, was reported. Recently, however, several instances of serious opportunistic infections have been reported. In the years following approval of fingolimod for use in multiple sclerosis (MS), seven cases of cryptococcal meningitis in patients undergoing treatment have been described in the literature. We present a 40-year old woman with RRMS on fingolimod therapy presenting with a rare case of cryptococcal meningitis exhibiting alterations of consciousness, which was initially diagnosed as an MS relapse.
芬戈莫德是一种口服药物，于2009年获得美国食品药品监督管理局批准，用于治疗复发缓解型多发性硬化症（RRMS）。最初的临床试验并未显示芬戈莫德治疗会显著增加严重感染的发生率。然而，有报告称，不太严重的感染（如水痘带状疱疹病毒和单纯疱疹病毒感染）的风险略有增加。然而，最近有几例严重机会性感染的报告。在芬戈莫德被批准用于治疗多发性硬化症（MS）后的几年里，文献中描述了7例接受治疗的患者发生隐球菌性脑膜炎的病例。我们报告一名40岁接受芬戈莫德治疗的RRMS女性患者，该患者出现罕见的隐球菌性脑膜炎，伴有意识改变，最初被诊断为MS复发。
